Opinion|Videos|July 18, 2024
Durability of Effect and Advice to Improve Quality of Life in Atopic Dermatitis
Author(s)Shawn Kwatra, MD
Shawn Kwatra, MD, discusses the durability of treatments for atopic dermatitis and provides advice for clinicians on improving patients’ quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How durable is the impact of AD treatments on patients’ QoL?
- What advice can you share with clinicians to improve the quality of life of patients with AD?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
4
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
5